Protagonist Therapeutics, Inc.
PTGX · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $46.0M | $434M | −89.4% |
| Operating income | −$158M | $253M | |
| Net income | −$130M | $275M |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 6, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $274M | $4.70M | +5,738% |
| Operating income | $218M | −$46.4M | |
| Net income | $220M | −$39.3M |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Protagonist's revenue in FY2025?
- $46.0M in FY2025 (Fiscal year ended Dec 31, 2025), −89.4% vs $434M a year earlier, per its 10-K filed Feb 2026.
- Was Protagonist profitable in FY2025?
- No: net income was −$130M and operating income −$158M in FY2025.
- What was Protagonist's revenue in Q3 2026?
- $274M (+5,738% vs a year earlier), per its Form 10-Q filed Nov 6, 2026.